Table 1.
Tumor Type | # of Tumors | % VEGFR2 Positive | % VEGFR2 Negative |
---|---|---|---|
SW480 xenograft | 4 | 60 ± 10.57a | 40 ± 12.61c |
Clinical colorectal carcinoma | 36 | 60 ± 3.06a | 40 ± 2.54c |
WM239 xenograft | 10 | 91.96 ± 3.01b | 8.04 ± 0.41d |
Clinical metastatic melanoma | 14 | 93 ± 3.29b | 7 ± 0.33d |
Table I - VEGFR2 heterogeneity was assessed in human clinical specimens and xenografts of both colorectal carcinoma and metastatic malignant melanoma using dual immunofluorescence staining for VEGFR2 and CD31. The mean values for average percentage of VEGFR2 positive and VEGFR2 negative vessels were calculated along with SEM. Values with the same superscript (a-m) are significantly different from the same vessel class in different cancer types, but not from each other (p < 0.05).